Skip to main content
Caplight Logo









Facio Therapies

Facio Therapies

Private
LeidenHealthcare & Life Scienceshttps://facio-therapies.com/

Last Round

M&A

Apr 6, 2021

Est. Valuation

$11.8M

Total Funding Raised

$835,000

Company Overview

Facio Therapies is a biotechnology company focused on developing causal therapies to treat facioscapulohumeral muscular dystrophy (FSHD) by restoring the natural repression of the DUX4 protein.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

Nonprofit or NGO

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

facioscapulohumeral muscular dystrophyFSHDdrug discoverysmall-molecule therapeuticsDUX4 genebiotechnologyorphan drugrare disease researchtherapeutic pipelinepreclinical developmentbiotech startupdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Facio Therapies Comparables

Compare Facio Therapies with similar companies based on industry and business-model similarity.

Facio Therapies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Altay Therapeutics
85%
Myocea, Inc.
84%
Epicrispr Biotechnologies
79%

Facio Therapies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AApr 6, 2021
GrantSep 1, 2020
GrantNov 1, 2018
VC RoundJun 20, 2017
GrantNov 1, 2016

Facio Therapies Investors

Notable investors and investment history

Facio Therapies investors
InvestorRounds
FSHD Canada FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 6, 2021

    $12M raised from uniQure N.V.

  • Sep 1, 2020

    $380K grant from FSHD Canada Foundation received.

Facio Therapies Filings

Explore SEC and related filing metadata, where available.

Facio Therapies filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Facio Therapies's valuation, stock price, and market status.

Is Facio Therapies a public or private company?

Facio Therapies is a private company.

What is the current stock price of Facio Therapies?

Facio Therapies is a private company with no public stock price. No recent secondary market data is available.

How much is Facio Therapies worth (valuation)?

Facio Therapies's valuation is estimated at $11.8M based on funding round data.

Can I buy Facio Therapies stock?

Facio Therapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Facio Therapies's last funding round?

Facio Therapies's most recent funding round was M&A on April 6, 2021.

Who are the main investors in Facio Therapies?

Key investors in Facio Therapies include FSHD Canada Foundation.

Will Facio Therapies IPO soon?

No public IPO plans have been announced for Facio Therapies.

How can I track Facio Therapies secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Facio Therapies's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLeiden
Year Founded2014
Last FundingApr 6, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?